Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tedizolid Phosphate

FDA-approved product (tablet, oral), marketed as Sivextro.

Registered studies
37
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tedizolid Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antibacterials
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX11

Repurposing investigation

Tedizolid Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tedizolid Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tedizolid Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

    NCT06609161 · start 2024-07-16

    Registered record
    Registry ID
    NCT06609161
    Conditions
    Healthy
    Interventions
    Tedizolid Phosphate Oral Formulation 1 (Reference); Tedizolid Phosphate Oral Formulation 2 (Test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-16
    Completion
    2024-08-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTedizolid Phosphate Oral Formulation 1 (Reference); Tedizolid Phosphate Oral Formulation 2 (Test)
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

    NCT05534750 · start 2023-04-20

    Registered record
    Registry ID
    NCT05534750
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis
    Interventions
    Tedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-20
    Completion
    2026-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis
    InterventionTedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

    NCT06733688 · start 2022-03-23

    Registered record
    Registry ID
    NCT06733688
    Conditions
    Healthy
    Interventions
    Tedizolid Phosphate Oral Formulation 1 (Reference); Tedizolid Phosphate Oral Formulation 2 (Test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-23
    Completion
    2022-04-15
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTedizolid Phosphate Oral Formulation 1 (Reference); Tedizolid Phosphate Oral Formulation 2 (Test)
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

    NCT03217565 · start 2019-02-06

    Registered record
    Registry ID
    NCT03217565
    Conditions
    Gram-Positive Infections
    Interventions
    IV Tedizolid Phosphate; Oral Suspension Tedizolid Phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-02-06
    Completion
    2023-04-06
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Infections
    InterventionIV Tedizolid Phosphate; Oral Suspension Tedizolid Phosphate
    PhasePhase 1
    Registry statusCompleted

  • A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

    NCT03176134 · start 2019-01-20

    Registered record
    Registry ID
    NCT03176134
    Conditions
    Acute Bacterial Skin and Skin Structure Infections
    Interventions
    Tedizolid phosphate; Comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-01-20
    Completion
    2023-07-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Skin and Skin Structure Infections
    InterventionTedizolid phosphate; Comparator
    PhasePhase 3
    Registry statusCompleted

  • Tedizolid Prolonged Treatment for Prosthetic Joint Infections

    NCT03378427 · start 2018-08-28

    Registered record
    Registry ID
    NCT03378427
    Conditions
    Prosthetic Joint Infection
    Interventions
    Tedizolid Phosphate 200 MG [Sivextro]
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-08-28
    Completion
    2021-08-22
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection
    InterventionTedizolid Phosphate 200 MG [Sivextro]
    PhaseNot applicable
    Registry statusCompleted

  • Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

    NCT03009045 · start 2017-02-06

    Registered record
    Registry ID
    NCT03009045
    Conditions
    Bone and Joint Infection
    Interventions
    Tedizolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-02-06
    Completion
    2021-08-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone and Joint Infection
    InterventionTedizolid
    PhasePhase 2
    Registry statusCompleted

  • Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study

    NCT02991131 · start 2016-12-17

    Registered record
    Registry ID
    NCT02991131
    Conditions
    Skin Disease, Infectious
    Interventions
    Tedizolid (Sivextro, BAY1192631); Linezolid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-12-17
    Completion
    2018-11-21
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Disease, Infectious
    InterventionTedizolid (Sivextro, BAY1192631); Linezolid
    PhaseNot recorded
    Registry statusTerminated

  • A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

    NCT02750761 · start 2016-05-02

    Registered record
    Registry ID
    NCT02750761
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    Tedizolid Phosphate (IV); Tedizolid Phosphate (oral suspension)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-02
    Completion
    2018-12-21
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    InterventionTedizolid Phosphate (IV); Tedizolid Phosphate (oral suspension)
    PhasePhase 1
    Registry statusCompleted

  • Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

    NCT02620787 · start 2016-02-23

    Registered record
    Registry ID
    NCT02620787
    Conditions
    Diabetes; Wound Infection; Healthy Volunteers
    Interventions
    Tedizolid; Microdialysis Catheter Insertion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2017-03-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Wound Infection; Healthy Volunteers
    InterventionTedizolid; Microdialysis Catheter Insertion
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

    NCT02444234 · start 2015-07

    Registered record
    Registry ID
    NCT02444234
    Conditions
    Cystic Fibrosis
    Interventions
    Tedizolid PO; Tedizolid IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-07
    Completion
    2017-12-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTedizolid PO; Tedizolid IV
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

    NCT02477514 · start 2015-06

    Registered record
    Registry ID
    NCT02477514
    Conditions
    Skin Diseases, Bacterial
    Interventions
    midazolam; rosuvastatin; tedizolid phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Bacterial
    Interventionmidazolam; rosuvastatin; tedizolid phosphate
    PhasePhase 1
    Registry statusCompleted

  • Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

    NCT02276482 · start 2015-03-25

    Registered record
    Registry ID
    NCT02276482
    Conditions
    Skin Diseases, Infectious; Skin Diseases, Bacterial
    Interventions
    Tedizolid Phophate; Antibiotic comparator; Aztreonam; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-03-25
    Completion
    2018-09-17
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious; Skin Diseases, Bacterial
    InterventionTedizolid Phophate; Antibiotic comparator; Aztreonam; Metronidazole
    PhasePhase 3
    Registry statusCompleted

  • Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

    NCT02342418 · start 2015-03

    Registered record
    Registry ID
    NCT02342418
    Conditions
    Obesity
    Interventions
    Tedizolid phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2015-12
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionTedizolid phosphate
    PhasePhase 4
    Registry statusCompleted

  • Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

    NCT02097043 · start 2014-05

    Registered record
    Registry ID
    NCT02097043
    Conditions
    Healthy
    Interventions
    DA-7218; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-05
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDA-7218; Placebo
    PhasePhase 1
    Registry statusCompleted